A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data

Wheeler, Graham M., Sweeting, Michael J. and Mander, Adrian P. ORCID: https://orcid.org/0000-0002-0742-9040 2019. A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data. Journal of the Royal Statistical Society: Series C 68 (2) , pp. 309-329. 10.1111/rssc.12323

PDF - Published Version Available under License Creative Commons Attribution. Download (942kB)

Abstract

The product of independent beta probabilities escalation design for dual agent phase I dose escalation trials is a Bayesian model‐free approach for identifying multiple maximum tolerated dose combinations of novel combination therapies. Despite only being published in 2015, the design has been implemented in at least two oncology trials. However, these trials require patients to have completed follow‐up before clinicians can make dose escalation decisions. For trials of radiotherapy or advanced therapeutics, this may lead to impractically long trial durations due to late‐onset treatment‐related toxicities. We extend the product of independent probabilities escalation design to use censored time‐to‐event toxicity outcomes for making dose escalation decisions. We show via comprehensive simulation studies and sensitivity analyses that trial duration can be reduced by up to 35%, particularly when recruitment is faster than expected, without compromising on other operating characteristics.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	Royal Statistical Society
ISSN:	0035-9254
Date of First Compliant Deposit:	29 April 2021
Date of Acceptance:	31 October 2018
Last Modified:	03 May 2023 22:05
URI:	https://orca.cardiff.ac.uk/id/eprint/140824

Citation Data

Cited 4 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item